tirzepatide patient information Big update in pediatric diabetes care 🩺 Mounjaro® (tirzepatide) is now FDA-approved for children ≥10 years old with Type 2 diabetes as an adjunct to diet and exercise. What this means ⬇️ Informed consent for tirzepatide (Mounjaro®)

Overall, the findings indicate that SGLT2 inhibitor therapy did not significantly alter the effects of semaglutide on reducing RARI and mitigating fibrosis

Can PT-141 Be Combined With Other Therapies

Contact us today to schedule an in-person appointment or virtual consult with an expert integrative physician

The Wegovy weight loss pen is suitable for individuals who want medically supervised weight reduction and meet the following criteria: Individuals with obesity (BMI 30) who need to reduce or manage weight for health reasons Individuals who are overweight (BMI 27) with weight-related conditions such as diabetes, hypertension, or heart disease Individuals who have attempted diet control and exercise but still struggle to reach their target weight Individuals with irregular eating behaviors, such as frequent snacking or overeating Individuals currently on a weight-loss journey and seeking an additional medical tool to enhance results Who Should Avoid the Wegovy Weight Loss Pen

October 2024: The MDL had just under 1,100 pending cases

Trusted generics Save with proven generics that are safe, effective, and clinically backed for the same reliable results